Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing

References

• Ballinger TJ, Sanders ME, Abramson VG. Current HER2 testing recommendations and clinical relevance as a predictor of response to targeted therapy. Clin Breast Cancer. 2015;15:171–180. doi:10.1016/j.clbc.2014.11.009
   PubMed Web of Science ®Google Scholar
• Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320–368. doi:10.1634/theoncologist.2008-0230
   PubMed Web of Science ®Google Scholar
• Gabos Z, Sinha R, Hanson J, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006;24:5658–5663. doi:10.1200/JCO.2006.07.0250
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28:92–98. doi:10.1200/JCO.2008.19.9844
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–145. doi:10.1200/JCO.2006.09.2775
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013. doi:10.1200/JCO.2013.50.9984
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. J Clin Oncol. 2018;36:2105–2122. doi:10.1200/JCO.2018.77.8738
   PubMed Web of Science ®Google Scholar
• Bhargava R, Dabbs DJ. Interpretation of human epidermal growth factor receptor 2 (HER2) in situ hybridization assays using 2013 update of American Society of Clinical Oncology/College of American Pathologists HER2 guidelines. J Clin Oncol. 2014;32:1855. doi:10.1200/JCO.2013.53.9213
   PubMed Web of Science ®Google Scholar
• Wang X, Teng X, Ding W, et al. A clinicopathological study of 30 breast cancer cases with a HER2/CEP17 ratio of ≥2.0 but an average HER2 copy number of <4.0 signals per cell. Mod Pathol. 2020;33:1557–1562. doi:10.1038/s41379-020-0519-y
   PubMed Web of Science ®Google Scholar
• Press MF, Sauter G, Buyse M, et al. HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in breast cancer international research group clinical trials. J Clin Oncol. 2016;34:3518–3528. doi:10.1200/JCO.2016.66.6693
   PubMed Web of Science ®Google Scholar
• Ballard M, Jalikis F, Krings G, et al. ‘Non-classical’ HER2 FISH results in breast cancer: a multiinstitutional study. Mod Pathol. 2017;30:227–235. doi:10.1038/modpathol.2016.175
   PubMed Web of Science ®Google Scholar
• Li A, Bai Q, Kong H, et al. Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2020;144:1097–1107. doi:10.5858/arpa.2019-0369-OA
   PubMed Web of Science ®Google Scholar
• Kong H, Bai Q, Li A, et al. Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline. Diagn Pathol. 2022;17. doi:10.1186/s13000-021-01187-z
   PubMed Web of Science ®Google Scholar
• Guo L, Yuan P, Zhang J, et al. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer. Breast Cancer Res Treat. 2017;166:77–84. doi:10.1007/s10549-017-4397-z
   PubMed Web of Science ®Google Scholar
• Hanna WM, Slodkowska E, Lu F-I, et al. Comparative analysis of human epidermal growth factor receptor 2 testing in breast Cancer according to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations. J Clin Oncol. 2017;35:3039–3045. doi:10.1200/JCO.2016.70.5319
   PubMed Web of Science ®Google Scholar
• Bethune GC, Zanten DVV, MacIntosh RF, et al. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as “equivocal” for HER2 gene amplification by fluorescence in-situ hybridization. Histopathology. 2015;67:880–887. doi:10.1111/his.12723
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu S, Shi X, et al. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor. Breast Cancer Res Treat. 2019;178:275–281. doi:10.1007/s10549-019-05387-6
   PubMed Web of Science ®Google Scholar
• Xu Y, Bai QM, Yang F, et al. Impact of 2013 American Society of Clinical Oncology/College of American Pathologist guidelines on borderline immunostaining results for HER2: a retrospective study on HER2 FISH results in 1780 cases of invasive breast cancers. Zhonghua Bing Li Xue Za Zhi. 2016;45:545–549. doi:10.3760/cma.j.issn.0529-5807.2016.08.010
   PubMedGoogle Scholar
• Press MF, Villalobos I, Santiago A, et al. Assessing the new American Society of Clinical Oncology/College of American Pathologists guidelines for HER2 testing by fluorescence in situ hybridization: experience of an academic consultation practice. Arch Pathol Lab Med. 2016;140:1250–1258. doi:10.5858/arpa.2016-0009-OA
   PubMed Web of Science ®Google Scholar
• Shah MV, Wiktor AE, Meyer RG, et al. Change in pattern of HER2 fluorescent in situ hybridization (FISH) results in breast cancers submitted for FISH testing: experience of a reference laboratory using US Food and Drug Administration criteria and American Society of Clinical Oncology and College of American Pathologists guidelines. J Clin Oncol. 2016;34:3502–3510. doi:10.1200/JCO.2015.61.8983
   PubMed Web of Science ®Google Scholar
• Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12:320–327. doi:10.1016/S0960-9776(03)00106-1
   PubMed Web of Science ®Google Scholar
• Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414–4422. doi:10.1200/JCO.2007.10.6823
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–2795. doi:10.1200/JCO.2009.25.6529
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24:2206–2223. doi:10.1093/annonc/mdt303
   PubMed Web of Science ®Google Scholar
• Cronin M, Sangli C, Liu ML, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem. 2007;53:1084–1091. doi:10.1373/clinchem.2006.076497
   PubMed Web of Science ®Google Scholar
• Qi P, Yang Y, Bai QM, et al. Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients. Breast Cancer Res Treat. 2021;186:327–342. doi:10.1007/s10549-020-06075-6
   PubMed Web of Science ®Google Scholar
• Park MM, Ebel JJ, Zhao W, et al. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment. Breast J. 2014;20:37–45. doi:10.1111/tbj.12223
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–121. doi:10.1056/NEJMoa1804710
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336–2347. doi:10.1056/NEJMoa2108873
   PubMed Web of Science ®Google Scholar
• Mittempergher L, Delahaye LJ, Witteveen A, et al. MammaPrint and BluePrint molecular diagnostics using targeted RNA next-generation sequencing technology. J Mol Diagn. 2019;21:808–823. doi:10.1016/j.jmoldx.2019.04.007
   PubMedGoogle Scholar
• Krijgsman O, Roepman P, Zwart W, et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat. 2012;133:37–47. doi:10.1007/s10549-011-1683-z
   PubMed Web of Science ®Google Scholar
• Mittempergher L, Delahaye LJ, Witteveen AT, et al. Performance characteristics of the BluePrint® breast cancer diagnostic test. Transl Oncol. 2020;13:100756. doi:10.1016/j.tranon.2020.100756
   PubMed Web of Science ®Google Scholar
• Whitworth P, Stork-Sloots L, de Snoo FA, et al. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST). Ann Surg Oncol. 2014;21:3261–3267. doi:10.1245/s10434-014-3908-y
   PubMed Web of Science ®Google Scholar
• Viale G, de Snoo FA, Slaets L, et al. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. Breast Cancer Res Treat. 2018;167:123–131. doi:10.1007/s10549-017-4509-9
   PubMed Web of Science ®Google Scholar
• Yang SR, Bouhlal Y, De La Vega FM, et al. Integrated genomic characterization of ERBB2/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups. Mod Pathol. 2020;33:1546–1556. doi:10.1038/s41379-020-0504-5
   PubMed Web of Science ®Google Scholar
• Dowsett M, Procter M, McCaskill-Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol. 2009;27:2962–2969. doi:10.1200/JCO.2008.19.7939
   PubMed Web of Science ®Google Scholar
• Perez EA, Reinholz MM, Hillman DW, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol. 2010;28:4307–4315. doi:10.1200/JCO.2009.26.2154
   PubMed Web of Science ®Google Scholar
• Arnould L, Arveux P, Couturier J, et al. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res. 2007;13:6404–6409. doi:10.1158/1078-0432.CCR-06-3022
   PubMed Web of Science ®Google Scholar
• Alhamar M, Alkamachi B, Mehrotra H, et al. Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents. Mod Pathol. 2021;34:720–734. doi:10.1038/s41379-020-00728-z
   PubMed Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9–20. doi:10.1056/NEJMoa2203690
   PubMed Web of Science ®Google Scholar
• Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22:1151–1161. doi:10.1016/S1470-2045(21)00301-6
   PubMed Web of Science ®Google Scholar
• Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of Trastuzumab Deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol. 2020;38:1887–1896. doi:10.1200/JCO.19.02318
   PubMed Web of Science ®Google Scholar